New safety check for Kids' leukemia drug BESPONSA
NCT ID NCT06476665
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is checking the safety of the drug BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL). The 10 participants have already been treated and are being watched for side effects, especially liver problems. The goal is to better understand the risks of this approved drug in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BESPONSA (inotuzumab ozogamicin)
- What this could lead to
- If successful, this study could confirm that BESPONSA is safe for children with a certain type of leukemia, supporting its continued use.
- What could go wrong
- This is a small, observational safety study with only 10 participants, so results may not apply to all patients. There is a known risk of liver problems with this drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New transplant recipe aims to tame Graft-Versus-Host disease
- Experimental drug RAD001 tested for tough leukemias and lymphomas
- Engineered immune cells take aim at returning blood cancers
- Selective immune cell removal may tame transplant complications
- New hope for tough blood cancers: LP-118 trial launches
- Blood cancer transplant trial using banked donor marrow pulled before start